David Wien, MD
Allergy & Immunology · Wilmington, DENPI 1912904038
Payments from drug & device makers
Across 560 payments — averaging $30.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Sanofi$2K
- Biocryst US Sales Co., LLC$871
- CSL Behring$865
- plus $4K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 140 | $3,515 |
| GSK | 117 | $3,445 |
| Regeneron Healthcare Solutions, Inc. | 34 | $2,346 |
| Sanofi | 54 | $1,645 |
| Biocryst US Sales Co., LLC | 33 | $871 |
| CSL Behring | 38 | $865 |
| Genentech USA, Inc. | 15 | $546 |
| Amgen(2 entities) | 26 | $544 |
| Pharming Healthcare, Inc. | 20 | $467 |
| Optinose US, Inc. | 14 | $412 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $284 |
| Alk-abello, Inc | 7 | $278 |
| Novartis | 10 | $201 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $165 |
| Grifols USA, LLC | 2 | $148 |
| Shire North American Group Inc | 2 | $141 |
| AbbVie | 1 | $125 |
| Lilly USA, LLC | 1 | $125 |
| Sanofi-aventis U.S. LLC | 2 | $121 |
| Boehringer Ingelheim | 1 | $95 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| Aimmune Therapeutics, Inc. | 4 | $66 |
| Merck | 3 | $61 |
| LEO Pharma Inc. | 3 | $58 |
| Pfizer | 3 | $57 |
| Biocryst Pharmaceuticals, Inc. | 2 | $34 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Ionis Pharmaceuticals, Inc. | 1 | $21 |
| Mckesson Medical-surgical, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
How this compares
Too few allergy & immunology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Wilmington
- Gregory MarcotteWilmington$17K
- Michael WydilaWilmington$7K
- Michelle SquadritoWilmington$5K
- Richard KimWilmington$4K
- Isma ShahWilmington$3K
- Trong leWilmington$220
- Junfang JiaoNewark$20K
- Sokun BhattiNewark$5K
- Lyvia LeighLewes$4K
- Muhammad KhalidNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.